Stoke Therapeutics
STOK
90 hedge funds and large institutions have $492M invested in Stoke Therapeutics in 2021 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 26 increasing their positions, 30 reducing their positions, and 15 closing their positions.
2.4% less ownership
Funds ownership: 55.07% → 52.67% (-2.4%)
7% less funds holding
Funds holding: 97 → 90 (-7)
13% less repeat investments, than reductions
Existing positions increased: 26 | Existing positions reduced: 30
28% less capital invested
Capital invested by funds: $680M → $492M (-$188M)
47% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 15
55% less call options, than puts
Call options by funds: $336K | Put options by funds: $745K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.96M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.03M |
| 3 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
+$2.77M |
| 4 |
Millennium Management
New York
|
+$1.53M |
| 5 |
HS
HighVista Strategies
Boston,
Massachusetts
|
+$1.33M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
-$22.6M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$7.85M |
| 3 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$3.42M |
| 4 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$3.26M |
| 5 |
BlackRock
New York
|
-$2.85M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
XT
101
XTX Topco
George Town,
Cayman Islands
| – | -$216K | -6,422 | Closed |
|
102
Amundi
Paris,
France
| – | -$178K | -5,300 | Closed |
|
|
PHK
103
Point72 Hong Kong
Hong Kong
| – | -$46K | -1,363 | Closed |
|
|
FWM
104
FFT Wealth Management
Philadelphia,
Pennsylvania
| – | -$10K | -300 | Closed |
|
|
TFA
105
Toth Financial Advisory
Leesburg,
Virginia
| – | -$2K | -60 | Closed |
|
STOK Hedge Fund Activity: Q3 2021 in Review
90 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in Stoke Therapeutics (STOK) for Q3 2021, worth a combined $492M — down 28% from $680M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of STOK and 8 opened new positions — a net loss of 7 holders — while 30 trimmed existing stakes and 26 added.
The largest buyer was Fidelity Investments, adding an estimated $8.96M. The largest seller was Perceptive Advisors, exiting entirely with an estimated $22.6M sold.
- 90 institutional investors held Stoke Therapeutics (STOK) as of Q3 2021, down from 97 in Q2 2021.
- Funds reported $492M of Stoke Therapeutics stock for Q3 2021, down 28% quarter-over-quarter.
- 8 funds opened new Stoke Therapeutics positions in Q3 2021 and 15 closed out, a net change of -7 holders.
- The largest Stoke Therapeutics buyer in Q3 2021 was Fidelity Investments, an estimated $8.96M added.
- The largest Stoke Therapeutics seller in Q3 2021 was Perceptive Advisors, an estimated $22.6M sold.
Based on aggregated 13F filings for Q3 2021.